Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients

Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB).Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and...